CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)

BTK plays an important role in B cell receptor and Toll-like receptor signaling pathways, which are constitutively active in primary CNS lymphomas, and hence represents an excellent therapeutic target. Ibrutinib, a first-generation BTKi, was evaluated in phase 1/2 trials for R/R PCNSL, SCNSL, and PV...

Descripción completa

Detalles Bibliográficos
Autores principales: Soussain, Carole, Grommes, Christian, Issa, Samar, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark, Steinberg, Marcos, Tun, Han W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354203/
http://dx.doi.org/10.1093/noajnl/vdac078.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354203/
http://dx.doi.org/10.1093/noajnl/vdac078.035

Ejemplares similares